» Articles » PMID: 35597928

Association of Bone-related biomarkers with Femoral Neck Bone Strength

Overview
Publisher Biomed Central
Specialties Orthopedics
Physiology
Date 2022 May 21
PMID 35597928
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Femoral neck fractures are the worst consequence of osteoporosis (OP), and its early prevention and treatment have become a public health problem. This study aims to investigate the relationship of bone-related biomarkers, femoral neck bone mineral density (BMD) and maximum load (L), selecting the indicator which can reflect femoral neck bone loss and reduced bone strength.

Methods: A total of 108 patients were recruited from January 2017 to December 2019. Venous blood samples were collected from patients before total hip replacement, and femoral neck samples were collected during the surgery. Femoral neck BMD, femoral neck L, bone-related markers (serum levels of bone turnover markers, protein expression of type I collagen (COL-I) and osteopontin (OPN) in femoral neck) were all measured and analyzed.

Results: The expression of COL-I in femoral neck were significantly decreased, whereas other markers were all significantly increased with the decreasing of femoral neck BMD and L (P < 0.05). Among them, serum C-terminal telopeptide of type I collagen (CTX) levels and OPN expression of femoral neck were increased in osteopenia. In multiple linear regression analysis, CTX and OPN were both negatively correlated with femoral neck BMD and L, and they were independent factors of femoral neck BMD and L, whereas COL-I was independent factor affecting L (P < 0.05). Besides, CTX was negatively correlated with COL-I (β = -0.275, P = 0.012) and positively correlated with OPN (β = 0.295, P = 0.003).

Conclusions: Compared with other indicators, serum CTX was more sensitive to differences in bone mass and bone strength of femoral neck, and could be considered as surrogate marker for OPN and COL-I.Early measurement of CTX could facilitate the diagnosis of osteopenia and provide a theoretical basis for delaying the occurrence of femoral neck OP and fragility fractures.

Citing Articles

Role of the Vitamin D Receptor (VDR) in the Pathogenesis of Osteoporosis: A Genetic, Epigenetic and Molecular Pilot Study.

Gasperini B, Visconti V, Ciccacci C, Falvino A, Gasbarra E, Iundusi R Genes (Basel). 2023; 14(3).

PMID: 36980815 PMC: 10048253. DOI: 10.3390/genes14030542.


The role of advanced glycation end products in fracture risk assessment in postmenopausal type 2 diabetic patients.

Gao L, Liu C, Hu P, Wang N, Bao X, Wang B Front Endocrinol (Lausanne). 2022; 13:1013397.

PMID: 36578954 PMC: 9790927. DOI: 10.3389/fendo.2022.1013397.

References
1.
Curtis E, Moon R, Harvey N, Cooper C . The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. 2017; 104:29-38. PMC: 5420448. DOI: 10.1016/j.bone.2017.01.024. View

2.
Singh S, Kumar D, Lal A . Serum Osteocalcin as a Diagnostic Biomarker for Primary Osteoporosis in Women. J Clin Diagn Res. 2015; 9(8):RC04-7. PMC: 4576601. DOI: 10.7860/JCDR/2015/14857.6318. View

3.
Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgstrom F . The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. J Bone Miner Res. 2019; 34(4):616-625. DOI: 10.1002/jbmr.3640. View

4.
Tarquini C, Mattera R, Mastrangeli F, Agostinelli S, Ferlosio A, Bei R . Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis. Amino Acids. 2016; 49(3):683-693. DOI: 10.1007/s00726-016-2290-4. View

5.
Marin L, Koivula M, Jukkola-Vuorinen A, Leino A, Risteli J . Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem. 2011; 48(Pt 5):447-51. DOI: 10.1258/acb.2011.011040. View